WaveMan
WaveMan · Company
DYN · Dyne Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

DYN Dyne Therapeutics (DYN) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001818794
Quote by TradingView
Form 144 · 12
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
139
13F, latest reported quarter

What the filings say about DYN

Insiders, 180 days
-$115.7M net sold
1 buyer · 6 sellers · 7% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$67.7M
12 notices

Dyne Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Dyne Therapeutics, Inc. insiders sold a net $115.7M of stock across 469 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Posner Brian S
Director
BUY
2026-10-06 SECtraded 2026-10-02
2,500
$40.0K
-2.2%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Jun 8, 2026.
  • +24.4% median (+27.1% mean) 90-day return after 7 previous buys.
  • The trade is 9.3% of the 27,000 shares held after it.
  • No other insider bought within 30 days.
  • 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Posner Brian S bought about $40.0K of DYN on Oct 2, 2026; 139 funds added in the latest 13F quarter.
Kerr Douglas
Chief Medical Officer
SELL
2026-09-08 SEC
1,290
$24.4K
-18.6%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Sep 4, 2026.
  • The trade is 0.8% of the 162,564 shares held after it.
  • 4 other insiders sold within 30 days.
  • 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Kerr Douglas sold about $24.4K of DYN under a 10b5-1 plan on Sep 8, 2026; 4 other insiders sold within 30 days and 139 funds added in the latest 13F quarter.
Cox John
CEO & President
SELL
2026-09-08 SEC
5,658
$106.8K
-18.6%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (3 buys, 8 sales), the last on Aug 13, 2026.
  • +20.5% median (+20.5% mean) 90-day return after 2 previous buys.
  • The trade is 1.6% of the 357,507 shares held after it.
  • 4 other insiders sold within 30 days.
  • 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO & President Cox John sold about $106.8K of DYN under a 10b5-1 plan on Sep 8, 2026; 4 other insiders sold within 30 days and 139 funds added in the latest 13F quarter.
Friedl-Naderer Johanna
Chief Commercial Officer
SELL
2026-09-08 SEC
185
$3.5K
-18.6%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Sep 4, 2026.
  • The trade is 0.1% of the 152,897 shares held after it.
  • 4 other insiders sold within 30 days.
  • 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Friedl-Naderer Johanna sold about $3.5K of DYN under a 10b5-1 plan on Sep 8, 2026; 4 other insiders sold within 30 days and 139 funds added in the latest 13F quarter.
Kerr Douglas
Chief Medical Officer
SELL
2026-09-08 SECtraded 2026-09-04
3,745
$91.2K
-18.6%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Aug 13, 2026.
  • The trade is 2.3% of the 163,854 shares held after it.
  • 4 other insiders sold within 30 days.
  • 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Kerr Douglas sold about $91.2K of DYN under a 10b5-1 plan on Sep 4, 2026; 4 other insiders sold within 30 days and 139 funds added in the latest 13F quarter.
469 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 464 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$115.7M over 180 days
-$65.6M over 90 days
below 98% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
139 funds bought in last quarter
more than 80% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
13.9% of the float short (float per yahoo 2026-10-26) · 9.0 days to cover · settled 2026-09-30
more than 82% of Pharma & Biotech
What changed in the last 30 days
Oct 6Director Posner Brian S bought $40.0K (Oct 2)

Watch DYN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-4.5%12M
-13%+13%+38%+64%2025-102025-122026-022026-042026-062026-082026-10 2026-08-14 · Rhodes Jason P sold $34.0M2026-08-14 · Rhodes Jason P sold $12.0M2026-08-14 · Rhodes Jason P sold $8.1M2026-08-13 · Rhodes Jason P sold $7.0M2026-07-27 · Kersten Dirk sold $6.5M2026-07-06 · Rhodes Jason P sold $5.8M2026-03-10 · Kersten Dirk sold $5.6M2026-04-17 · Kersten Dirk sold $4.3M2026-03-10 · Kersten Dirk sold $4.2M2026-06-22 · Kersten Dirk sold $3.9M2026-06-26 · Rhodes Jason P sold $3.5M2026-03-09 · Kersten Dirk sold $3.1M2026-04-22 · Rhodes Jason P sold $3.0M2026-07-06 · Rhodes Jason P sold $2.9M2026-07-07 · Rhodes Jason P sold $2.9M2026-04-20 · Rhodes Jason P sold $2.9M2026-04-21 · Rhodes Jason P sold $2.8M2026-03-11 · Kersten Dirk sold $2.5M2026-04-20 · Kersten Dirk sold $2.5M2026-08-13 · Rhodes Jason P sold $2.5M2026-07-06 · Rhodes Jason P sold $2.3M2026-04-28 · Rhodes Jason P sold $2.2M2026-06-29 · Rhodes Jason P sold $2.2M2026-06-26 · Rhodes Jason P sold $1.7M2026-08-13 · Rhodes Jason P sold $1.7M2026-04-15 · Kersten Dirk sold $1.7M2026-04-27 · Rhodes Jason P sold $1.7M2026-06-23 · Rhodes Jason P sold $1.6M2026-06-23 · Kersten Dirk sold $1.5M2026-04-22 · Rhodes Jason P sold $1.5M2026-07-07 · Rhodes Jason P sold $1.4M2026-04-20 · Rhodes Jason P sold $1.4M2026-04-21 · Rhodes Jason P sold $1.4M2026-06-26 · Rhodes Jason P sold $1.4M2026-04-24 · Rhodes Jason P sold $1.3M2026-04-22 · Rhodes Jason P sold $1.2M2026-07-07 · Rhodes Jason P sold $1.1M2026-04-20 · Rhodes Jason P sold $1.1M2026-04-28 · Rhodes Jason P sold $1.1M2026-04-21 · Rhodes Jason P sold $1.1M2026-06-29 · Rhodes Jason P sold $1.1M2026-06-24 · Rhodes Jason P sold $1.1M2026-09-08 · Cox John filed to sell $106.8K2026-09-08 · Kerr Douglas filed to sell $6612026-09-04 · Kerr Douglas filed to sell $121.7K2026-08-14 · Atlas Venture Fund XI, LP filed to sell $35.3M2026-08-14 · Atlas Venture Opportunity Fund I, LP filed to sell $8.4M2026-08-14 · Atlas Venture Opportunity Fund II, LP filed to sell $12.4M2026-08-13 · Atlas Venture Fund XI, LP filed to sell $7.0M2026-08-13 · Atlas Venture Opportunity Fund I, LP filed to sell $1.7M2026-08-13 · Atlas Venture Opportunity Fund II, LP filed to sell $2.5M2026-08-13 · Cox John filed to sell $131.0K2026-08-13 · Kerr Douglas filed to sell $64.2K2026-08-13 · Lucera Erick filed to sell $47.2K2026-07-27 · ForDyne B.V. filed to sell $6.7M2026-07-07 · ATLAS VENTURE ASSOCIATES XI, L.P. filed to sell $114.2K2026-07-07 · Atlas Venture Fund XI, LP filed to sell $3.5M2026-07-07 · Atlas Venture Opportunity Fund I, LP filed to sell $1.4M2026-07-07 · Atlas Venture Opportunity Fund II, LP filed to sell $1.8M2026-07-06 · Atlas Venture Fund XI, LP filed to sell $5.8M2026-07-06 · Atlas Venture Opportunity Fund I, LP filed to sell $2.3M2026-07-06 · Atlas Venture Opportunity Fund II, LP filed to sell $2.9M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns DYN: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
12,404,330 sh
$275.5M
Jupiter Topco LLC
11,997,738 sh
$266.6M
FMR LLC
11,207,000 sh
$248.9M
STATE STREET CORP
7,458,263 sh
$165.6M
Orbis Allan Gray Ltd
7,006,542 sh
$155.6M

Congress trades in DYN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

DYN planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Cox John
Filed 2026-09-08
$106.8K
Kerr Douglas
Filed 2026-09-08
$661
Kerr Douglas
Filed 2026-09-04
$121.7K
Atlas Venture Fund XI, LP
Filed 2026-08-14
$35.3M
Atlas Venture Opportunity Fund I, LP
Filed 2026-08-14
$8.4M

DYN mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Wasatch Ultra Growth Fund
$9.6M position · as of 2026-06-30
2.1%
T. Rowe Price Health Care ETF
$467.9K position · as of 2026-06-30
2.0%
T. Rowe Price Institutional Small-Cap Stock Fund
$84.6M position · as of 2026-06-30
1.7%
T. Rowe Price Small-Cap Stock Fund, Inc.
$155.6M position · as of 2026-06-30
1.7%
NYLIM Fiera SMID Growth Fund
$2.6M position · as of 2026-07-31
1.3%
Franklin Biotechnology Discovery Fund
$13.1M position · as of 2026-07-31
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 3
2 active
2
Multi-phase
2 active
What changed recently
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 i
2026-09-24 · Recruiting → Active Not Recruiting
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $115.7M sold by insiders over 180 days, 139 funds added last quarter, $67.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

DYN financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$480.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.28x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-2.40x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-11.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-8.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-67.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$2.4B
market value at close 2026-10-23 on 2026-07-24 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-16.5%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$468.2M-$343.9M-$242.2M-$171.0M
Net income-$446-$317-$236-$168
EPS (diluted)-3.47-3.37-3.95-3.23
Operating cash flow-$403.2M-$292.4M-$188.2M-$153.6M
Cash$893.4M$435.4M$121.6M$172.1M
Long-term debt$148.9M$0n/an/a
SEC XBRL, fiscal years, as known on 2026-10-27

DYN Stock Sonar score 5/7 axes

Find similar shapesCompare

DYN ranks highest on profitability (63rd percentile) and institutional and government (43rd), and lowest on risk and compliance (27th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
63
Inputs
  • Return on equity-11.5% · 76 pct, sector of 545
  • Return on assets-8.5% · 75 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-67.0% · 38 pct, sector of 576
Financial health
41
Inputs
  • Debt to equity0.28x · 40 pct, sector of 352
  • Cash flow to debt-2.40x · 42 pct, sector of 371
Insider conviction
29
Inputs
  • Net Form 4 buying (codes P and S), 180d-$115.4M · 2 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
43
Inputs
  • Funds adding, latest quarter139 · 80 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$40K · 6 pct, sector of 133
Risk and compliance
27
Inputs
  • Short interest, % of float+13.9% · 27 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

DYN filings, in plain words

Are Dyne Therapeutics insiders buying or selling DYN?

In the 180 days to 2026-10-27, Dyne Therapeutics insiders were net sellers, a net $115.7M: $196.8K of purchases and $115.9M of sales reported on Form 4, by 1 buyer and 6 sellers.

Are there planned insider sales of DYN?

Yes. 12 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $67.7M of stock; the latest, by Cox John, was filed 2026-09-08.

Read the full summary

In the 180 days to 2026-10-27, Dyne Therapeutics insiders were net sellers of DYN, a net $115.7M across purchases and sales reported on Form 4 by 1 buyer and 6 sellers. Sales outweighed purchases more than tenfold by value. 7% of the 67 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 12 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $67.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies